Abstracts tagged "interferons and neutrophils"

Abstract Number: 2652 • 2017 ACR/ARHP Annual Meeting
Abnormal Expression of Long Noncoding RNA Lncrna-CMPK2 Facilitates Neutrophils Interferon Production By TLR7/8 Agonist Stimulation in SLE
Zhixin Xue, Yuanjia Tang and Nan Shen, Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Interferon plays prominent role in systemic lupus erythematosus (SLE) pathogenesis while the source of high interferon in SLE is still confused, several cell types…
Abstract Number: 77 • 2014 ACR/ARHP Annual Meeting
Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils
Patrick Coit¹, Sri Yalavarthi¹, Wenpu Zhao², Mariana J. Kaplan² and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Lupus neutrophils play an important role in tissue damage (including glomerulonephritis and lupus skin involvement), as well as endothelial damage in lupus patients. Several…
Abstract Number: 2822 • 2013 ACR/ARHP Annual Meeting
IKKε Deficiency Prolongs Neutrophil Survival Paradoxically Prolonging Inflammation In The Absence Of a Type I Interferon Response
Maripat Corr¹, Christopher Chung², Seong-Kyu Kim³, D. L Boyle⁴ and G. S. Firestein⁵, ¹Medicine, Univ of California-San Diego, La Jolla, CA, ²Medicine, UCSD School of Medicine, La Jolla, CA, ³Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Deficiency of the IKK-related kinases IKKε synergizes with the anti-inflammatory effects of IFNß in a murine model of arthritis., and this effect is mediated…
Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting
Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow
Anna Bird¹, Nida Meednu², Javier Rangel-Moreno³, Srilakshmi Yalavarthi⁴, Jennifer Barnard¹, Teresa Owen⁵, Jason S. Knight⁶, Alfred Rabinovich¹, Arumugam Palanichamy², Jane Liesveld⁷, Jason W Bauer⁸, Emily Baechler⁹, Mariana J. Kaplan¹⁰ and Jennifer H. Anolik¹¹, ¹Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴University of Michigan Rheumatology, Ann Arbor, MI, ⁵Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, ⁸University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ¹¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].